Sunho Biologics (02898) Releases February 2026 Monthly Return

Bulletin Express

03/02

Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized share capital remains at 200.00 million ordinary shares, each with a par value of USD 0.0005, amounting to USD 100,000. The number of issued shares remains unchanged at 156.67 million, with no treasury shares reported.

The public float requirement for its listed ordinary shares is confirmed at 25%, and no changes in share options, warrants, or convertible securities were noted for the reporting period. The document was submitted by Chairman and Executive Director Zhang Feng.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1198797795"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198797795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198797795?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198797795","market":"hk","top_or_hot":-1,"title":"Sunho Biologics (02898) Releases February 2026 Monthly Return","media":"Bulletin Express","content":"<p>Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized share capital remains at 200.00 million ordinary shares, each with a par value of USD 0.0005, amounting to USD 100,000. The number of issued shares remains unchanged at 156.67 million, with no treasury shares reported.</p>\n<p>The public float requirement for its listed ordinary shares is confirmed at 25%, and no changes in share options, warrants, or convertible securities were noted for the reporting period. The document was submitted by Chairman and Executive Director Zhang Feng.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sunho Biologics (02898) Releases February 2026 Monthly Return</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSunho Biologics (02898) Releases February 2026 Monthly Return\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-02 17:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized share capital remains at 200.00 million ordinary shares, each with a par value of USD 0.0005, amounting to USD 100,000. The number of issued shares remains unchanged at 156.67 million, with no treasury shares reported.</p>\n<p>The public float requirement for its listed ordinary shares is confirmed at 25%, and no changes in share options, warrants, or convertible securities were noted for the reporting period. The document was submitted by Chairman and Executive Director Zhang Feng.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02898","symbol_name":"盛禾生物-B","start_time":0,"source_url":"","article_id":"1198797795","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198797795","pubTimestamp":1772443614,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02898":"盛禾生物-B"},"translate_title":"顺和生物(02898)发布2026年2月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02898":1},"content_text":"Sunho Biologics, Inc. (02898) submitted its Monthly Return for Equity Issuer for the period ended 28 February 2026 on 02 March 2026. According to the announcement, the company’s total authorized share capital remains at 200.00 million ordinary shares, each with a par value of USD 0.0005, amounting to USD 100,000. The number of issued shares remains unchanged at 156.67 million, with no treasury shares reported.\nThe public float requirement for its listed ordinary shares is confirmed at 25%, and no changes in share options, warrants, or convertible securities were noted for the reporting period. The document was submitted by Chairman and Executive Director Zhang Feng.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}